MedPath

Preemptive Lung Impedance-Guided Therapy in Evolving Acute Heart Failure in Acute Myocardial Infarction Patients

Phase 3
Completed
Conditions
Heart Failure
Registration Number
NCT01616121
Lead Sponsor
Hillel Yaffe Medical Center
Brief Summary

It is well-known that 20-25% of patients hospitalized for acute myocardial infarction will develop acute heart failure during their hospitalization. Currently, the investigators have no reliable parameter for prediction of evolving acute heart failure in such a group of patients. As a result, the investigators have no way of preventing acute heart failure. Treatment of these patients only begins after appearance of clinical signs of acute heart failure. Lung impedance monitoring may be a good non-invasive parameter for prediction of evolving acute heart failure. This study will attempt to address whether preemptive lung impedance-guided therapy may prevent the development of overt acute heart failure and improve their clinical outcome.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
654
Inclusion Criteria
  • Patients hospitalized in the ICCU for acute myocardial infarction and developing acute heart failure
Exclusion Criteria
  • Patients with acute myocardial infarction with clinical and radiological signs of acute heart failure at admission

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Prevention of acute heart failure development in acute MI patientsThree years
Secondary Outcome Measures
NameTimeMethod
Improvement of clinical outcome in patients with lung impedance-guided treatmentsThree years

Trial Locations

Locations (1)

Hillel Yaffe Medical Center

🇮🇱

Hadera, Israel

Hillel Yaffe Medical Center
🇮🇱Hadera, Israel

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.